Unlock instant, AI-driven research and patent intelligence for your innovation.

Cx43-mediated arteannuin B combined with cisplatin against lung cancer effect and related mechanism

An artemisinin and anti-lung cancer technology, applied in the field of medicine, can solve problems such as intercellular communication barriers and GJ dysfunction

Inactive Publication Date: 2020-06-30
于荣敏
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, once the expression level of Cx, which is regulated by various factors and mechanisms, changes, it will affect the GJ channel formed by it, resulting in abnormal GJ function, and causing obstacles to intercellular communication, which will lead to the occurrence of various diseases including tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cx43-mediated arteannuin B combined with cisplatin against lung cancer effect and related mechanism
  • Cx43-mediated arteannuin B combined with cisplatin against lung cancer effect and related mechanism
  • Cx43-mediated arteannuin B combined with cisplatin against lung cancer effect and related mechanism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The effect of artemisinin B on gap junction

[0020] (1) Parachute assay

[0021] 1) Cell inoculation: Take the cells in the logarithmic growth phase, digest and resuspend them in medium for counting, and adjust the cell density to 1.5×10 5 Cell / mL is then inoculated in a 12-well plate, placed at 37℃, 5% CO 2 Incubate in an incubator for 48 hours for subsequent experiments.

[0022] 2) Preparation of loading solution: add 12.5 μL calcein-AM (1 mg / mL) to 487.5 μL serum-free medium by pipetting and mixing, so that the final concentration of calcein-AM is 25 μM.

[0023] 3) Preparation of "donor cells": select 1 well of cells as "donor cells", discard the supernatant, wash once with PBS, and add 500 μL of the above-mentioned prepared load solution. 12-well plate placed at 37℃, 5% CO 2 Continue to incubate for 30 min in the incubator. Aspirate and discard the loading solution, wash with PBS 3 times, 5 min each time. Trypsin digestion of the "donor cell" wells, centrifugation, res...

Embodiment 2

[0073] Study on the combined effect of artemisinin B and DDP in vitro

[0074] (1) MTT experiment

[0075] 1) Cell inoculation: discard the old culture medium in the culture flask, wash once with PBS, add trypsin digestion and centrifuge, centrifuge at 1000 rpm for 5 min, discard the supernatant, add complete medium to resuspend, and count on a hemocytometer. Adjust the cell concentration to 3×10 4 cell / mL for plating, add 100μL of cell suspension to each well of a 96-well plate, set a blank control group, and place it at 37℃, 5% CO 2 Cultivate in a cell incubator for 24 hours to make the cells grow adherently.

[0076] 2) Dosing treatment: After 24 hours, discard the supernatant, add the prepared liquids of different concentrations in the corresponding 96-well plate area, and add an equal volume of complete medium to the negative control group. The 96-well plate was placed in a cell incubator and incubated for 72 hours.

[0077] 3) Color reaction: Add 20μL / well of 5mg / mL MTT solutio...

Embodiment 3

[0091] Study on the combined effect of artemisinin B and DDP in vivo

[0092] 1) Establishment of tumor model: trypsinize A549 cells in logarithmic growth phase and collect them in a 15mL centrifuge tube; centrifuge at 1000rpm for 10min, discard the supernatant, and save the cell pellet; wash once with PBS, centrifuge at 1000rpm for 10min, and discard Clear, add PBS solution to resuspend, gently pipette to mix into a single cell suspension; use a hemocytometer to count, adjust the cell suspension concentration to 5×10 6 cell / mL; disinfect the right axilla of nude mice with 75% alcohol in the ultra-clean platform, and inject 0.2mL cell suspension per mouse subcutaneously. After the nude mice are inoculated with tumor cells, observe the tumor formation every day, weigh and measure the tumor volume every other day, when the tumor volume reaches 100mm 3 At that time, randomized administration.

[0093] 2) Animal grouping and administration:

[0094]

[0095] Observe the changes of the n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of arteannuin B in synergy and attenuation of cisplatin against lung cancer. The important point of the invention is that the inventors find that combination ofthe arteannuin B and the cisplatin has an additive and synergistic effect in vitro, and the combination in vivo can also effectively inhibit the proliferation of xenograft tumors in nude mice and delay the occurrence of cisplatin toxicity, and the inventors preliminary verify that the effect of the arteannuin B on the cisplatin is related to cell-to-cell communication. The research results specifically include the following aspects: the arteannuin B can enhance Cx43 expression and intercellular GJ function in A549 cells; the Q value of the combined effect of the arteannuin B and the cisplatinis in the range of 0.85<=Q<=1.15 and Q>1.15; in-vivo experiment results show that the tumor tissue necrosis degree of the arteannuin B combined with cisplatin is greater than that of a medication group alone, and the degree of spleen injury is less than that of a cisplatin group; and in addition, Westernblotting results in vitro and in vivo also show that the combination of the arteannuin B and the cisplatin up-regulates the expression of Cx43 protein, and enhances the activation of MAPKs. Therefore, the arteannuin B can enhance the anti-lung cancer effect of the cisplatin through the cell communication mechanism and reduce the toxic and side effects to a certain extent, and the result has potential clinical application value.

Description

Technical field [0001] The invention relates to the technical field of medicine, in particular to the application of artemisinin B to the anti-tumor effect of positive drug cisplatin in enhancing efficacy and reducing toxicity. Background technique [0002] Artemisia annua (Artemisia annua L.) is an annual herb of the genus Compositae, also known as Artemisia annua, Artemisia annua, and Artemisia annua. It is widely distributed and has strong adaptability. It has the effects of relieving heat, relieving fever, and curing colds. , Is a traditional Chinese herbal medicine in my country. Artemisinin is a sesquiterpene lactone compound with antimalarial activity extracted from Artemisia annua by Chinese pharmaceutical workers in 1972. Clinically, artemisinin and its derivatives can quickly kill malaria parasites with significant curative effect and no obvious side effects. In addition, recent studies have shown that in addition to antimalarial activity, artemisinin compounds also ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/243A61K31/365A61P35/00
CPCA61K33/24A61K31/365A61P35/00A61K2300/00
Inventor 于荣敏宋丽艳许雅芳朱建华
Owner 于荣敏